Opdivo, Keytruda Hit Again As Japan Revises Prices

Immuno-oncology drugs Opdivo and Keytruda will have their prices cut in the next regular Japanese price revision in April, while some other novel and big-selling products will also feel the heat under a revised framework.

Japanese yen
JAPAN PRICE REVISION HITS OPDIVO, OTHERS

The reimbursement prices of big-selling immuno-oncology products Opdivo (nivolumab) and Keytruda (pembrolizumab) are to be cut again at the time of the general drug price revision in Japan on April 1, adding to earlier one-off reductions for the two PD-1 inhibitors.

The reimbursement level awarded by Japan’s national health insurance will be reduced by around 24% and 11% respectively for the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia